Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport
Contact Us
Search
Close

Antitrust in China’s pharma sector – Bengbu action following big-bang reform

By Adrian Emch, Roy Zou, Andrew McGinty, Jessie Xie, Eugene Chen & Jiaming Zhang on September 1, 2015
Email this postTweet this postLike this postShare this post on LinkedIn

On 26 August 2015, the National Development and Reform Commission (NDRC) made public its first antitrust enforcement decision in the pharmaceutical sector since launching the drug pricing reform earlier this year. Although the target of this enforcement action was a local government entity, pharmaceutical companies should expect continued antitrust intervention in parallel with the implementation of the pricing reform.

Read more

Photo of Adrian Emch Adrian Emch
Read more about Adrian EmchEmail
Photo of Roy Zou Roy Zou
Read more about Roy ZouEmail
Photo of Andrew McGinty Andrew McGinty
Read more about Andrew McGintyEmail
  • Posted in:
    Antitrust, Competition and Trade
  • Blog:
    Focus on Regulation
  • Organization:
    Hogan Lovells
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
  • About LexBlog
  • The Field We Built
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo